Stock NGM NGM BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases NGM Biopharmaceuticals, Inc.

Equities

NGM

US62921N1054

Delayed Nasdaq
Other stock markets
 16:00:00 2024-04-04 EDT 		5-day change 1st Jan Change
1.54 USD -1.28% Intraday chart for NGM Biopharmaceuticals, Inc. -.--% +79.28%
04-05 NGM Biopharmaceuticals, Inc.(NasdaqGM:NGM) dropped from NASDAQ Composite Index CI
04-05 The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. from other group of shareholders. CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NGM Bio Announces Closing of Tender Offer
GL
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
GL
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
BU
NGM Biopharmaceuticals: Q4 Earnings Snapshot
AQ
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
GL
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
BU
NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders
BU
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
GL
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
AQ
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
GL
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
GL
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
GL
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
AQ
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
GL
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
AQ
NGM Bio to Participate in Upcoming Investor Conferences
GL
NGM Bio to Participate in Upcoming Investor Conferences
AQ
NGM Biopharmaceuticals: Q3 Earnings Snapshot
AQ
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
GL
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis Due to NASH at Upcoming AASLD the Liver Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NGM Stock
  4. News NGM Biopharmaceuticals, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW